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of a pro-ictogenic brain environment. We examine the participation of MLVs in the neuroimmune interaction, in response to brain-derived antigens.
| Lymphatic vessels: basic functions
New knowledge of MLVs is emerging, 3, 4, [6] [7] [8] including the anatomic localization and the implication for draining of solutes and immune cells. However, the exact functions of MLVs in both healthy and pathological conditions remain to be characterized. Due to shared anatomical and functional aspects between meningeal and peripheral lymphatic vessels, we here refer to the latter to revise the lymphatic system fundamental aspects. In the periphery, lymphatic vessels develop in close association with veins in the subcutaneous tissues and alongside arteries in the viscera. Lymphatic capillaries are constituted of a thin wall of endothelial cells, with smooth muscle cells and an adventitia layer present in larger vessels. The existence of openings in the endothelium and specialized valves allows for the collection of interstitial fluid, molecules, and proteins that have leaked from adjacent blood vessels due to damage or pressure changes, cleaning the tissue from the accumulating by-products. 9 Anatomic and functional defects of the peripheral lymphatic system result in the disruption of drainage and the development of lymphedema (accumulation of protein-rich fluid). 10, 11 Primary lymphedema is caused by congenital mutations in the genes involved in lymphatic vessel development (eg, Vascular endothelial growth factor receptor 3 ). Secondary lymphedema is a consequence of increased tissue pressure following trauma or tumors compressing the vessels, surgeries (eg, the removal of lymph nodes), scar tissue, chronic venous insufficiency, obesity, and infections (eg, filariasis, first cause of lymphedema in developing countries). 11 Each of these conditions can result in the overload of lymphatic transport capacity due to the obstruction or interruption of lymphatic vessels, favoring edema formation. The lymphatic system is also a key player in immune surveillance. 12 Lymphatic vessels drain soluble and cellassociated antigens from the tissues into regional lymph nodes, where they are presented to T and B lymphocytes via specialized antigen-presenting cells (APCs). The interaction between APCs, lymphocytes, and the lymph node environment establishes whether naive lymphocytes will mount an effector response, become tolerant, or undergo apoptosis to avoid autoimmunity. Therefore, lymphatic vessels play a central role in immune-cell activation and differentiation.
13,14
| The meningeal lymphatic vessels
In the CNS, the lymphatic vessels are located in the dura mater facing the subarachnoid space, lining the dural sinuses (the sinuses on the calvarium and the pterygopalatine and the middle meningeal arteries on the cranial base; Figure 1) ) the authors observed a reduced clearance of tracers (including ovalbumin) from the brain and a defect in drainage toward the dcLNs. These results suggest that CSF, ISF, and the meningeal lymphatic flows are functionally connected and contribute as a whole to interstitial clearance. Building from this evidence, here we specify a CNS-lymphatic unit, constituted by the structures allowing ISF and CSF movement (ventricles, perivascular space, and basement membrane of capillaries) and the MLVs. Impaired clearance of toxic molecules (eg, amyloid beta or pTau) is a trait of neurodegenerative diseases contributing to neuronal hyperexcitability (Box 2). Therefore, a functional modification of the CNS-lymphatic unit could be pathologic.
| ROLE OF MENINGEAL LYMPHATIC VESSELS IN CNS IMMUNE SURVEILLANCE

| T cells in the CNS lymph nodes
The role of adaptive immunity in the pathophysiology of CNS diseases is emerging. [71] [72] [73] Here we address the mechanisms F I G U R E 1 Schematic representation of lymphatic flow (light blue) located in the meninges, at the calvarium and cranial fossa (dorsal and ventral side of the cranium). A, In the calvarium, MLVs are located along the dural sinuses and the middle meningeal artery (red), as well as along the rostral rhinal vein and the tentorium around the pineal gland. B, C In the cranial fossa, MLVs are along the pterygopalatine artery (red), the optic and trigeminal nerves, the hypophysis, and the IX-XI cranial nerves. MLVs cover the spinal canal, exiting together with the cranial nerves toward the lymph nodes (C). FM, foramen magnum; MLVs, meningeal lymphatic vessels; MMA, middle meningeal artery; PPA, pterygopalatine artery; RRV, rostral rhinal vein; SSS, sinus sagittalis superior; ST, sinus transversus; TG, trigeminal nerve of adaptive neuroimmunity, focusing on the link between MLVs, dcLNs, and T-cell activation. Available studies point to a pivotal role of dcLNs in CNS immune surveillance. 16, [74] [75] [76] As previously demonstrated, 16, 77 the immune response to CNS-derived antigens is regional. Antigens drained from the CSF or present in the meninges trigger a Tcell response, 77 whereas antigens expressed in the brain parenchyma induce preferably a humoral immune reaction. 16 CSF-ISF clearance (Box 1 and Figure 3 ) follows distinct pathways (ventricles, periventricular organs, subarachnoid and parenchyma space, or cortical and subcortical regions) determining specific antigen-draining routes toward secondary lymphoid organs, perhaps influencing the immune response ( Figure 4 ). ISF drains mainly to the dcLNs, 4,27 while solutes present in the CSF flow into both scLNs and dcLNs, as well as to lumbar LNs. 19, [78] [79] [80] In the dcLNs, brain-derived antigens elicit a CNS-specific T-helper immune response (Section 3.2), whereas immune response triggered in the superficial or lumbar lymph nodes has been proposed to be skewed toward CD8+ T-cell activation. 81 
| Role of deep cervical lymph nodes in brain immune tolerance and response
By injecting immunogenic tumor-derived antigen directly into the brain parenchyma, Harling-Berg and colleagues demonstrated that, in the dcLNs, the evoked immune response is T-helper type 2 (Th2) and B-cell mediated, resulting in antibody production. 16 Injuries to the CNS (eg, optic nerve injury) promote a similar immune response associated with the upregulation increase of regulatory T cells (T reg , a cell subpopulation pivotal in maintaining tolerance to self-antigens and in preventing autoimmune disease, 82 Figure 4 ). Dissimilarly, in the peripheral lymphatic organs, CNS-derived antigens elicit a cytotoxic immune response (CD8+ T-cell mediated), without activation of the T reg subpopulation. 82, 83 The source of the CNSderived antigens (parenchymal vs meningeal) may determine the lymph nodes to which the antigens drain to, eventually influencing the immune response. This was proposed as a mechanism to provide brain protection from pathogen infection, at the same time preserving neurons from autoimmune attacks. 84 Of
Box 1: CNS fluids
The cerebrospinal (CSF) and the interstitial fluid (ISF) are the principal fluid components of the CNS. The CSF is an ultrafiltrate of blood plasma, with a low protein content in the ventricles. At spinal cord level, protein concentration in the CSF is higher and includes a component of white blood cells. Its main functions are to protect the brain (buoyancy and shock absorption), to maintain brain homeostasis, and to accumulate waste products, (eg, brain cell metabolites). The CSF is produced by the choroid plexus (up to 80%) filling the lateral, third, and fourth ventricles, while the remaining 20% may derive from the ependymal cells lining the ventricles and from the subarachnoid space. 19, 20 The CSF circulates through the ventricles, the cisterns, and fills the subarachnoid space, and may re-enter the cortex via dispersion along large caliber arteries/arterioles. 19, 21 A component of the CSF flows along the Virchow-Robin space and in the perivascular space (pia and the glia limitans). The CSF is also assumed to enter the periventricular organs directly from the ventricles 22 ( Figure 2) . The CSF has a pulsatile flow (along the antero-posterior axis), as systolic and diastolic pressure changes impact CSF flow velocity and direction 21 . The CSF exits the CNS via the arachnoid villi into the sinus sagittalis superior or flows to the nasal lymphatics through the cribriform plate and along principal nerve routes (olfactory, optic, and spinal nerves, where MLVs are also located; Figure 3) . The ISF fills the extracellular space within the brain parenchyma (15%-20% of total brain volume). 23 The ISF has a unique composition of ions, proteins, peptides, and neurotransmitters, essential to maintain the isotonicity of the brain cellular microenvironment. 20 The ISF derives at the BBB from secretion processes, where water follows ionic transport into the brain and across the endothelium (reviewed in Brinker et al 19 ). Starling's forces (oncotic vs hydrostatic pressure) control the production of BBB exudate in disease conditions, when serum proteins can access the brain. Movement of ISF in the extracellular space may follow diffusion and convection mechanisms. However, the relative contribution of the two remains to be defined. 21, 22 The interchange and mixing between the CSF and ISF is difficult to estimate, as it may vary de- The first 2 pathways allow for ISF-CSF interchange, whereas the third one assumes a direct flow of ISF to the MLVs. Clearance of molecules from the CNS was proposed to be compartmentalized: solute drainage from the brain parenchyma occurs along the perivascular pathways into the dcLNs, 27 whereas CSF from ventricles and subarachnoid spaces drain to both scLNs and dcLNs [27] [28] [29] (Figure 3 ). Modifications of CSF-ISF drainage due to congenital malformations or as result of lymphatic vessel obstruction could generate proinflammatory conditions due to solute and cell accumulation, promoting neuroimmune reactions.
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Box 2: pTau accumulation and neuronal hyperexcitability
Deposits of hyperphosphorylated tubulin-associated protein (pTau) are correlated with neurodegeneration and axonal injury in patients with epilepsy and in experimental models (for a comprehensive review see Ali et al, 51 Saletti et al, 52 and Zheng et al 53 ). Accumulation of pTau was reported in brain specimens obtained from patients with focal cortical dysplasia or acquired epilepsy (eg, post-traumatic), 47, [54] [55] [56] as well as in temporal lobe epilepsy patients with no history of TBI. 57, 58 Results were corroborated by using experimental models of epilepsy 59 or of TBI associated with the development of seizures. 60 ,61 pTau has been implicated in the regulation of neuronal network synchronization 62, 63 and in neuroplasticity changes 64, 65 resulting in hyperexcitability. 63 In a murine model of Alzheimer disease, the reduction of pTau levels corresponded to decreased electroencephalographic seizures. 62 From a pharmacologic point of view, 66,67 the administration of sodium selenate (a potent activator of tau phosphatase PP2A) resulted in the decrease of pTau and in the reduction of network hyperexcitability or seizure susceptibility, 68 as well as in the inhibition of epileptogenesis. 69 These results support pTau as a common component of neurodegenerative diseases, including acquired epilepsies. 70 As accumulation of pTau is associated with neuronal network excitability, favoring pTau clearance could result in an antiepileptic effect. The MLVs are afferent to the dcLNs. 4 We speculate that functional obstruction of MLVs could result in a detour of brain-derived antigens toward alternative secondary lymphatic organs (eg, scLNs, lumbar lymph nodes, or spleen), circumventing the regulation of the neuroimmune response provided by the dcLNs. As a result, the antigens drained from the brain could promote a cytotoxic CD8-mediated auto immune reaction. Our preliminary data obtained using K14flt4-tg mice (lacking MLVs and dcLNs) support this hypothesis showing CD8+ T-cell immune response specifically in the cortical areas surrounding the lesion in a model of traumatic brain injury (TBI; controlled cortical injury [CCI] delivered unilaterally to the somatosensory cortex).
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| MENINGEAL LYMPHATIC VESSELS AND THE DEVELOPMENT OF AUTOIMMUNE ENCEPHALITIDES
The International League Against Epilepsy (ILAE) has included autoimmunity among the etiologies of epilepsy: "immune epilepsy is the direct result of an immune disorder, in which seizures are a core symptom, and the hallmark is the presence of autoimmune-mediated brain inflammation". 85 Autoimmune encephalitides are classified as follows: (a) encephalitides with pathogenic antibodies against cell surface proteins (eg, anti-NMDA [N-methyl-d-aspartate] receptor, anti-LGI1, anti-VGKC complex); (b) T-cell diseases against intracellular antigens (eg, GAD65); and (c) encephalitides associated with other autoimmune disorders (eg, lupus cerebritis). 86 Seizures and status epilepticus are common symptoms in autoimmune encephalitides, 87 which can be resistant to antiepileptic drugs (AEDs) and respond better to immune therapies. 88 Autoimmune encephalitides can relapse, 86 suggesting the presence of a functional defect in the immune surveillance of the CNS.
| CNS-lymphatic unit and Rasmussen encephalitis pathophysiology: a proposed link
Here we focus on Rasmussen encephalitis (RE), described as focal seizures due to chronic localized encephalitis of probable viral origin. 89 RE is a slow-progressing neurologic disorder, characterized by unilateral brain atrophy and the presence of active microglia/macrophage nodules. 90, 91 RE is associated with focal aware or focal impaired awareness seizures with motor onset, or with focal to bilateral tonic-clonic seizures, and poor response to AEDs. 92 Studies performed using brain specimens obtained from RE patients have indicated the presence of brain-infiltrating cytotoxic CD8+ T cells undergoing clonal local expansion. [93] [94] [95] The infiltrating CD8+ T cells are juxtaposed to neurons and astrocytes, with granzyme-B-containing granules polarized toward neuronal or astrocytic membranes. In his original paper, 89 Rasmussen proposed a brain viral infection as the initiating event eliciting the CD8+ T-cell immune response. This would explain the clonal composition of the T-cell receptor repertoire found in the brain of RE patients 94 and the observed hemispheric distribution with centrifugal expansion, 96 suggestive of a focal infection. However, no sign of viral infection has been found in brain specimens obtained from RE patients. 96 Here we propose the hypothesis (Figure 4 ) that the CD8+ -mediated immune response observed in RE may be the result of insufficient lymphatic drainage, either congenital (as in primary lymphedema) or consequent to the obstruction of the lymphatic flow. Under this condition, the control of the neuroimmune response provided by the MLVs-dcLNs may fail and brain-derived antigens could reach the peripheral lymph nodes, where a cytotoxic CD8+ T-cell mediated response occurs. Activated CD8+ T cells could home back to the brain and selectively target those cells (ie, neurons or glia) expressing the self-antigen. This could result in the specific neuronal and astrocytic cell loss observed in RE brains. 97, 98 A possible objection to our hypothesis is that autoimmune responses are usually not focal, whereas RE is. However, localized brain infiltration of activated CD8+ T cells may be facilitated in areas of BBB dysfunction and ongoing neuroinflammation. The latter could be the consequence of a cellular imprint of precedent insults and of a regional damage following head trauma or hypoxic events. 99 Under these conditions, proinflammatory cytokines can upregulate the expression of adhesion molecules (ICAM-1, VCAM-1, and E-selectin) on endothelial cells. 100 These factors bind to specific ligands expressed by the activated leukocytes allowing the adhesion, rolling, and migration of activated T cells across the brain endothelium 79 . In summary, RE could therefore be the result of a double-hit, specifically a, reduced CNS-lymphatic unit efficiency (activating autoimmune T cells) and a brain insult, inducing regional neuroinflammation and BBB dysfunction, that promotes focal lymphocyte CNS recruitment.
| CNS-LYMPHATIC UNIT IMPAIRMENT AND MODULATORY APPROACHES
Strategies aimed at regenerating the lymphatic system may represent a supporting therapeutic intervention. It is known that inflammation can directly promote lymphangiogenesis, an extensive and localized growth of lymphatic vessels. 102 The newly-formed lymphatic vessels contribute to restore the fluid drainage and counteract the inflammatory processes. [102] [103] [104] [105] It is therefore possible to exploit lymphangiogenic mechanisms to restore a compromised lymphatic system. For instance, the lymphangiogenesis-inducing factor VEGF-C can be administered locally to recover lymphatic drainage. The administration of the soluble form of the human recombinant (hr)VEGF-C 106 or its localized viral vectors-mediated over-expression 107, 108 resulted in growth of functional and mature lymphatic vessels in animal models of peripheral lymphedema. Similarly, intracerebroventricular injections of adenoviral VEGF-C vector induced the growth of lymphatic capillaries in the meningeal compartment. 109 However, the functionality of these newly generated MLVs is uncertain, and further studies are required to decipher the ability of the new lymphatic vessels to clear parenchymal solutes and to control neuroimmunity.
| CONCLUDING REMARK S
Experimental evidence points to MLVs as a structural component of the CNS-lymphatic unit, impacting brain homeostasis, solute interstitial clearance, immune surveillance or inflammation. We have reviewed how alterations of the physiologic drainage of brain fluids could determine the accumulation of macromolecules within the brain parenchyma, resulting in the alteration of the extracellular ionic equilibrium, ultimately impacting neuronal excitability. The correct drainage of brain-derived antigens could be important for the allostasis of the neuroimmune cross-talk. We updated the hypothesis supporting the involvement of dcLNs in immune CNS surveillance and proposed that functional alterations of the MLVs (primary afferent vessels of the dcLNs) could result in autoimmune reactions. We suggested that a dysfunction of the CNS-lymphatic unit could be implicated in the pathophysiology of specific forms of epilepsy, as in situations where the primary cause is unknown (eg, Rasmussen encephalitis). Moreover, functional of the CNS-lymphatic unit due to congenital defects or as a result of brain trauma, tumors, or infections could contribute to acquired or immune epilepsies. Addressing the dynamics of the CNS-lymphatic unit in the context of ictal activity could be important to disclose new therapeutic targets.
